Reyon Pharmaceutical Co Ltd (102460) — Working Capital to Net Assets Ratio
Reyon Pharmaceutical Co Ltd (102460) has a Working Capital to Net Assets ratio of -23.1% as of September 2025. Working capital of ₩-53.78 Billion (current assets of ₩81.98 Billion minus current liabilities of ₩135.76 Billion) is measured against net assets of ₩233.12 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 102460 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Reyon Pharmaceutical Co Ltd Working Capital to Net Assets (2008–2024)
This chart shows how Reyon Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2008 to 2024. As of September 2025, the ratio stands at -23.1%, reflecting working capital of ₩-53.78 Billion against net assets of ₩233.12 Billion KRW. See operational self-sufficiency of Reyon Pharmaceutical Co Ltd to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Reyon Pharmaceutical Co Ltd (2008–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Reyon Pharmaceutical Co Ltd from 2008 to 2024, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 102460 market cap.
| Year | WC/NA Ratio | Working Capital (KRW) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | -18.4% | ₩-46.09 Billion | ₩249.94 Billion | ₩89.44 Billion | ₩135.54 Billion | ▼ -8.1 pp |
| 2023 | -10.4% | ₩-25.79 Billion | ₩248.62 Billion | ₩99.81 Billion | ₩125.60 Billion | ▼ -35.0 pp |
| 2022 | 24.6% | ₩61.05 Billion | ₩247.77 Billion | ₩109.01 Billion | ₩47.95 Billion | ▼ -23.2 pp |
| 2021 | 47.8% | ₩117.30 Billion | ₩245.24 Billion | ₩164.80 Billion | ₩47.50 Billion | ▲ +17.8 pp |
| 2020 | 30.0% | ₩69.02 Billion | ₩230.09 Billion | ₩117.77 Billion | ₩48.75 Billion | ▼ -13.8 pp |
| 2019 | 43.8% | ₩97.27 Billion | ₩222.29 Billion | ₩130.31 Billion | ₩33.03 Billion | ▼ -37.0 pp |
| 2018 | 80.7% | ₩181.92 Billion | ₩225.39 Billion | ₩224.42 Billion | ₩42.51 Billion | ▲ +14.1 pp |
| 2017 | 66.6% | ₩146.21 Billion | ₩219.66 Billion | ₩161.69 Billion | ₩15.48 Billion | ▲ +11.8 pp |
| 2016 | 54.8% | ₩98.08 Billion | ₩179.10 Billion | ₩116.77 Billion | ₩18.69 Billion | ▼ -10.2 pp |
| 2012 | 65.0% | ₩82.14 Billion | ₩126.36 Billion | ₩109.84 Billion | ₩27.70 Billion | ▼ -11.7 pp |
| 2011 | 76.7% | ₩80.94 Billion | ₩105.47 Billion | ₩108.41 Billion | ₩27.47 Billion | ▲ +6.0 pp |
| 2009 | 70.7% | ₩42.26 Billion | ₩59.76 Billion | ₩62.06 Billion | ₩19.80 Billion | ▲ +1.7 pp |
| 2008 | 69.0% | ₩29.41 Billion | ₩42.63 Billion | ₩49.34 Billion | ₩19.92 Billion | — |